NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 14 September 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Peter Selby (Vice Chair) Present for all items
3. Michael Chambers Present for all items
4. Dr Prithwiraj Das Items 1 to 4.3.2
5. Dr David Foreman Present for all items
6. Dr Rob Forsyth Present for all items
7. Dr Natalie Hallas Present for all items
8. John Hampson Items 1 to 4.3.2
9. Dr Nigel Langford Present for all items
10. Dr Andrea Manca Present for all items
11. Iain McGowan Present for all items
12. Dr Richard Nicholas Present for all items
13. Stella O’Brien Present for all items
14. Professor Subhash Pokhrel Present for all items
15. Professor Andrew Renehan Present for all items
16. Professor Matthew Stevenson Present for all items
17. Professor Paul Tappenden Present for all items
18. Dr Derek Ward Present for all items

NICE staff present

Ross Dent, Associate Director Items 1 to 4.3.2

Jasdeep Hayre, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Present for all items

Gavin Kenny, Project Manager Items 5 to 5.2.2

Alexandra Filby, Health Technology Assessment Adviser Items 1 to 4.3.2

Charlie Hewitt, Health Technology Assessment Adviser Items 5 to 5.2.2

Caron Jones, Health Technology Assessment Adviser Items 5 to 5.2.2

Kirsty Pitt, Health Technology Assessment Analyst Items 1 to 4.3.2

Nigel Gumbleton, Health Technology Assessment Analyst Items 5 to 5.2.2

Catherine Parker, Health Technology Assessment Analyst Items 5 to 5.2.2

Catrin Austin, Technical Analyst, Centre for Guidelines Items 1 to 4.3.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Korin Knight, Senior Medical Editor Items 1 to 4.3.2

Emilene Coventry, Senior Medical Editor Items 5 to 5.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Present for all Items

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 1 to 4.3.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 4.1.3 to 4.3.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.2.1

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.1.3

Lucinda Evans, Coordinator, MIP Items 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all items

James Devine, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 4.3.2

Ismahan Abdullah, Administrator, TA Items 5 to 5.2.2

External review group representatives present

Lorna Aucott, Aberdeen HTA Group Items 1 to 4.2.1

Charlotte Kennedy, Aberdeen HTA Group Items 1 to 4.2.1

Graham Scotland, Aberdeen HTA Group Items 1 to 4.2.1

Joanne Lord, Southampton Health Technology Assessment Centre (SHTAC)

Items 5 to 5.1.3

Jonathan Shepherd, Southampton Health Technology Assessment Centre (SHTAC)

Items 5 to 5.1.3

Clinical & patient experts present

Professor Peter Clark, National Clinical Lead for Cancer drugs fund, NHS England, Items 1 to 4.3.2

Dr Mike Dennis, Consultant Haematologist, clinical expert nominated by Royal College of Physicians, Items 1 to 4.2.1

Charlotte Martin, Patient expert nominated by Leukaemia Care, Items 1 to 4.2.1

Dr Elspeth Payne, Associate Clinical Professor/Consultant haematologist, clinical expert nominated by The Royal College of Pathologists, Items 1 to 4.2.1

Dr Sonya Craig, Consultant in Sleep and Respiratory Physician, clinical expert nominated by British Thoracic Society, Items 5 to 5.1.3

Graham Hill, Patient expert nominated by Sleep Apnoea Trust Association (SATA), Items 5 to 5.1.3

Dr Ari Manuel, Consultant in Sleep Medicine, clinical expert nominated by Lincoln Medical, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 11 August 2021.

### Appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (ID1564)

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical & patient experts, National Clinical lead for cancer drugs fund, external review group representatives, members of the public and company representatives from AbbVie.
		2. The chair asked all committee members, clinical & patient experts, National Clinical lead for cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has attended an advisory Board for Pfizer in an unrelated disease area.
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Nominated patient expert Charlotte Martin declared direct – non financial interests as she has been an employee of Leukaemia Care since June 2018.
* It was agreed that her declaration would not prevent Charlotte from providing expert advice to committee.
* Nominated clinical expert Dr Elspeth Payne declared financial interests as she has received honoraria for talks and advisory boards from Celgene, a BMS company.
* It was agreed that her declaration would not prevent Dr Payne from providing expert advice to committee.
* No further conflicts were declared for this Item.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Michael Chambers, Dr David Foreman and Stella O’Brien.
	1. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (company representatives, clinical and patient experts, and external review group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Determination Document (FAD). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10478>

### Appraisal of solriamfetol for treating excessive waketime sleepiness caused by obstructive sleep apnoea [ID1499]

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical & patient experts, external review group representatives, members of the public and company representatives from Jazz Pharmaceuticals.
		2. The chair asked all committee members, clinical & patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has provided consultancy advice to Shire Pharmaceuticals [potential comparator], in disease areas unrelated to this appraisal and most recently in late 2017. Shire is now part of Takeda Pharmaceuticals, with whom Michael currently has a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again unrelated to the topic of this appraisal.
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory board for Novartis, Biogen, and Roche in the field of multiple sclerosis treatments.
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Nominated clinical expert Dr Sonya Craig declared a financial interest as she is currently sitting on an advisory board for pitolisant which is another drug for excessive daytime sleepiness. She has declared this interest to the company making Solriamfetol and she says they were not concerned. She has also attended the ERS conference in Madrid 2019 paid for by Bioprojet who make pitolisant. Sonya confirmed she had not received payment.
* It was agreed that her declaration would not prevent Dr Craig from providing expert advice to the committee.
* Nominated clinical expert Dr Ari Manuel declared a financial interest as he carried out a lecture for Lincoln medical on the pathophysiology of OSA in April 2020 and was paid £400. He has also attended the international education meeting [USA/European based zoom] – where he talked on the need for more education in sleep medicine and was paid £1600.
* It was agreed that his declaration would not prevent Dr Manuel from providing expert advice to the committee.
* No further conflicts were declared for this Item.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10430>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 13 October 2021 and will start promptly at 9.30am.